China Aesthetic Injectable Market, 2026-2033
Global Market
Related Markets
China aesthetic injectable market highlights
- The China aesthetic injectable market generated a revenue of USD 2,321.6 million in 2025 and is expected to reach USD 5,811.2 million by 2033.
- The China market is expected to grow at a CAGR of 12.1% from 2026 to 2033.
- In terms of segment, botulinum toxin (botox) was the largest revenue generating product in 2025.
- PN/PDRN is the most lucrative product segment registering the fastest growth during the forecast period.
Aesthetic injectable market data book summary
| Market revenue in 2025 | USD 2,321.6 million |
| Market revenue in 2033 | USD 5,811.2 million |
| Growth rate | 12.1% (CAGR from 2026 to 2033) |
| Largest segment | Botulinum toxin (botox) |
| Fastest growing segment | PN/PDRN |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Collagen and PMMA Microspheres, Hyaluronic Acid, Calcium Hydroxylapatite (CaHA), PLLA, PCL, PN/PDRN, Botulinum Toxin (Botox) |
| Key market players worldwide | Ipsen SA, AbbVie Inc, Merz Pharma, Galderma Group AG Registered Shares, Prollenium Medical Technologies, Suneva Medical, Sinclair Pharma plc, Medytox, Revance Therapeutics Inc |
Other key industry trends
- In terms of revenue, China accounted for 20.9% of the global aesthetic injectable market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China aesthetic injectable market is projected to lead the regional market in terms of revenue in 2033.
- Vietnam is the fastest growing regional market in Asia Pacific and is projected to reach USD 72.1 million by 2033.
According to a report by Gengmei in 2019, nearly 25 million cosmetic surgeries were performed in China. In addition, the average age of patients declined to 24 years in 2019, and approximately 38% were aged between 20 and 25 years.
The increasing number of procedures in the young population highlights the high demand for such procedures. Moreover, the presence of major players is driving the market. For instance, Bloomage Biotechnology, one of the world’s largest producers of HA-based dermal fillers, is headquartered in China, which drives innovations & product acceptability, contributing to market growth.
Furthermore, in June 2023, Bloomage Biotech announced a project to construct an ecosystem focused on HA production. Consequently, Bloomage Biotech and Jinan High-tech Zone will jointly develop the project, and the former firm will contribute USD 37 billion.
No credit card required*
Publish Date: Apr 28, 2026
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Aesthetic Injectable Market
Aesthetic Injectable Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| AbbVie Inc | View profile | 50,000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | www.abbvieinvestor.com |
| Galderma Group AG Registered Shares | View profile | - | Zählerweg 10, Zug, Switzerland, 6300 | www.galderma.com |
| Revance Therapeutics Inc | View profile | 597 | 1222 Demonbreun Street, Suite 2000, Nashville, TN, United States, 37203 | www.revance.com |
| Merz Pharma | View profile | 5001-10000 | Deutsch, Sachsen, Germany, Europe | www.merz.com |
| Suneva Medical | View profile | 101-250 | San Diego, California, United States, North America | sunevamedical.com |
| Prollenium Medical Technologies | View profile | 101-250 | Richmond Hill, Ontario, Canada, North America | prollenium.com |
| Sinclair Pharma plc | View profile | 501-1000 | London, England, United Kingdom, Europe | www.sinclairpharma.com/ |
| Medytox | View profile | 501-1000 | Seoul, Seoul-t'ukpyolsi, South Korea, Asia | www.medytox.com/page/company_en?site_id=en |
| Ipsen SA | View profile | 5,325 | 65 Quai Georges Gorse, Billancourt Cedex, Boulogne, France, 92100 | www.ipsen.com |
China Aesthetic Injectable Market
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Aesthetic Injectable Market will help companies and investors design strategic landscapes.
Botulinum Toxin (Botox) was the largest segment with a revenue share of 53.61% in 2025.
Horizon Databook has segmented the China aesthetic injectable market based on collagen and pmma microspheres, hyaluronic acid, calcium hydroxylapatite (caha), plla, pcl, pn/pdrn, botulinum toxin (botox) covering the revenue growth of each sub-segment from 2021 to 2033.
According to a report by Gengmei in 2019, nearly 25 million cosmetic surgeries were performed in China. In addition, the average age of patients declined to 24 years in 2019, and approximately 38% were aged between 20 and 25 years.
The increasing number of procedures in the young population highlights the high demand for such procedures. Moreover, the presence of major players is driving the market. For instance, Bloomage Biotechnology, one of the world’s largest producers of HA-based dermal fillers, is headquartered in China, which drives innovations & product acceptability, contributing to market growth.
Furthermore, in June 2023, Bloomage Biotech announced a project to construct an ecosystem focused on HA production. Consequently, Bloomage Biotech and Jinan High-tech Zone will jointly develop the project, and the former firm will contribute USD 37 billion.
- China Aesthetic Injectable Market Product Outlook (Revenue, USD Million , 2021-2033)
- Collagen and PMMA Microspheres
- Hyaluronic Acid
- Calcium Hydroxylapatite (CaHA)
- PLLA
- PCL
- PN/PDRN
- Botulinum Toxin (Botox)
- China Aesthetic Injectable Market Application Outlook (Revenue, USD Million , 2021-2033)
- Wrinkle Correction
- Lip Augmentation
- Facial Contouring
- Scar Treatment
- Volume Loss Restoration
- Others
- China Aesthetic Injectable Market End Use Outlook (Revenue, USD Million , 2021-2033)
- MedSpas
- Aesthetic Surgery Centers
- Hospitals
- Others
Reasons to subscribe to Aesthetic Injectable Market databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Aesthetic Injectable Market databook
- Our clientele includes a mix of Aesthetic Injectable Market companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China Aesthetic Injectable Market, including forecasts for subscribers. This country databook contains high-level insights into China Aesthetic Injectable Market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
China Aesthetic Injectable Market, 2021-2033 (US$M)
China Product - Aesthetic Injectable Market, 2025 - 2033 (US$M)
